FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/03/083336 [Registered on: 25/03/2025] Trial Registered Prospectively
Last Modified On: 10/03/2025
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda
Radiation Therapy 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   A Study to Compare Add on Ayurvedic Treatment Versus Only Conventional Care in Modern Medicine to Improve Quality of Life for Advanced Head and Neck Cancer Patients 
Scientific Title of Study   Efficacy of Comprehensive Ayurvedic Treatment (CAT) as Add-On to Conventional Bio-Medicine in Improving the Quality of Life (Qol) in Unresectable Stage III-IVB Head-Neck Squamous Cell Carcinoma (HNSCC) Patients: An Assessor Blind Randomized Controlled Trial, CATCH Trial 
Trial Acronym  CATCH 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Gayatri Muthiyan 
Designation  Additional Professor 
Affiliation  All India Institute Of Medical Sciences Nagpur 
Address  Room No. 107, First floor Department of Anatomy, College Buidling, AIIMS Nagpur,Plot no. 2, MIHAN, Nagpur
All India Institute Of Medical Sciences Nagpur Plot no.2, Sector-20, MIHAN, Nagpur 441108
Nagpur
MAHARASHTRA
441108
India 
Phone  9322870196  
Fax    
Email  gayatrimuthiyan@aiimsnagpur.edu.in  
 
Details of Contact Person
Scientific Query
 
Name  Dr Gayatri Muthiyan 
Designation  Additional Professor 
Affiliation  All India Institute Of Medical Sciences Nagpur 
Address  Room No. 107, First floor Department of Anatomy, College Buidling, AIIMS Nagpur,Plot no. 2, MIHAN, Nagpur
All India Institute Of Medical Sciences Nagpur Plot no.2, Sector-20, MIHAN, Nagpur 441108
Nagpur
MAHARASHTRA
441108
India 
Phone  9322870196  
Fax    
Email  gayatrimuthiyan@aiimsnagpur.edu.in  
 
Details of Contact Person
Public Query
 
Name  Dr Amit Nakanekar 
Designation  Assistant Professor, Kayachikitsa 
Affiliation  Government Ayurvedic College and Hospital Nagpur 
Address  Department of Kayachikitsa Government Ayurvedic College Raje Raghuji Nagar, Sakkardara , Nagpur
Chota Tajbag Road, Ayurvedic Layout, Sakkardara Chowk, Nagpur, Maharashtra 440024
Nagpur
MAHARASHTRA
440024
India 
Phone  9850233016  
Fax    
Email  amitnakanekar@gmail.com  
 
Source of Monetary or Material Support  
All India Instituite of Medical Sciences Nagpur, Plot No 2, Sector 20, MIHAN, Nagpur, Maharashtra - 440008 (India) 
Indian Council of Medical Research (Ministry of Health & Family Welfare, Govt. of India), Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi 110029 (India) 
Ministry of AYUSH, Central Council for Research in Ayurvedic Sciences, Jawaharlal Nehru Bharatiya Chikitsa Evam Homoeopathy Anusandhan Bhawan, No 61-65,Institutional Area, Opp D block, Janakpuri, New Delhi 110058 (India) 
 
Primary Sponsor  
Name  Indian Council of Medical Research and Central Council for Research in Ayurvedic Sciences 
Address  Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi-29 and JNBCEH Anusandhan Bhawan, No 61-65, Opp D block, Janakpuri, New Delhi-58 (India) 
Type of Sponsor  Research institution 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Gayatri Muthiyan  All India Institute of Medical Sciences Nagpur  Ayush-ICMR Advanced Centre for Integrative Health Research (AI-ACIHR), Room No. 34-37, First floor, AYUSH building, AIIMS Nagpur, Plot No.2, Sector 20, MIHAN, Nagpur -440008 (India)
Nagpur
MAHARASHTRA 
9322870196

gayatrimuthiyan@aiimsnagpur.edu.in 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
AIIMS Nagpur  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:C148||Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx. Ayurveda Condition: ARBUDAH, (2) ICD-10 Condition:C01||Malignant neoplasm of base of tongue. Ayurveda Condition: ARBUDAH, (3) ICD-10 Condition:C13||Malignant neoplasm of hypopharynx. Ayurveda Condition: ARBUDAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Comparator Arm (Non Ayurveda)-Standard of Care Coventional Treatment Module1. Patients will be given conventional radiotherapy total dose of 70 Gy in 35 fractions over 7 weeks (2 Gy/fraction, 5 days in a week) to gross primary and nodal disease along with concurrent cisplatin 40 mg/m2 per week. 2. The cisplatin-based therapy will be administered for 5-7 cycles 3. Prior to administration of cisplatin, the standard of care will be initiated that includes Inj. Dexamethasone 16 mg (2 amp), Inj Ranitidine 50 mg (1 amp) and Inj Ondansetron 8 mg (1 amp) in 500 ml 0.9% NS for 45 minutes. 4. This will be followed by administration of 500 ml 0.9% NS for 45 minutes. Then, Inj Mannitol (20%) 100 ml over 15-20 minutes will be administered. 5. Following this, cisplatin 40 mg/m2 per week will be administered in 500 ml 0.9% NS for 60 minutes. 6. Finally, Inj KCl 20 mmol and Inj MgSO4 10 mmol in 1000 ml of 0.9% NS is administered for 2 hours
2Intervention ArmDrugOther than Classical(1) Medicine Name: Ayush Qol 2C, Reference: NA, Route: Oral, Dosage Form: Capsules, Dose: 1(g), Frequency: bd, Bhaishajya Kal: Abhakta, Duration: 6 Months, anupAna/sahapAna: Yes(details: warm water), Additional Information: All the Ayurvedic medicines and Procedures will be done as a add on to standard of care module
3Intervention ArmProcedure-mAtrAbastiH, मात्राबस्तिः (Procedure Reference: Ashtanga Hridayam Sutrasthan, Procedure details: 3. Three cycles of Matra Basti (each cycle 8 days) Narayan taila[42] (80 ml-100ml) [API, Part II, Vol IV])
(1) Medicine Name: Narayana Taila, Reference: 42. Tripathi B ,Sharangdhara Samhita:,(Dipika hindi commantary);, Chaukhamba Surabharti Prakashan Varanasi,2016,Madhyamkhanda, Adhyaya 9,page no .153 shlock 101-110 , Route: Rectal, Dosage Form: Taila, Dose: 100(ml), Frequency: od, Duration: 24 Days
4Intervention ArmDrugOther than Classical(1) Medicine Name: Conventional Standard of Care, Reference: NA, Route: Topical, Dosage Form: Capsules, Dose: 40(mg), Frequency: od, Bhaishajya Kal: Adhobhakta, Duration: 8 Weeks, anupAna/sahapAna: No, Additional Information: Conventional Standard of Care as per Comparator arm will be given . Ayurvedic treatment will be add on to Standard of care treatment
5Intervention ArmProcedure-nasyam/ nastam, नस्यम्/ नस्तम् (Procedure Reference: Ashtang Hridayam Sutrasthan, Procedure details: One cycle of Nasya (7 days) with Panchtikta Ghrit (4-10 drops in each nostril once a day))
(1) Medicine Name: Panchtikta Ghrit, Reference: API, Part II, Vol I, Route: Nasal, Dosage Form: Ghrita, Dose: 10(drops), Frequency: od, Duration: 7 Days
6Intervention ArmProcedure-kavalaH, कवलः (Procedure Reference: Ashtang Hridayam Sutrasthan, Procedure details: Kawal (Gargles) with decoction of Triphala and Yashtimadhu Churna twice daily)
(1) Medicine Name: Triphala and Yashtimadhu Kwath, Reference: Sharangdhara Samhita,Madhyamkhanda, Adhyaya 2 and Dravyaguna viyana vol II, Route: Topical, Dosage Form: Kwatha/Kashaya, Dose: 200(ml), Frequency: bd, Duration: 6 Months
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  70.00 Year(s)
Gender  Both 
Details  1) Unresectable histologically proven Head and Neck Squamous cell carcinoma patients,
2) Head and neck cancer with stage III to IVB
3) Age group of 18 to 70 years
4) Eastern Co operative Oncology Group ECOG performance status grade 0 to 1,
5) Haematological profile Haemoglobin level greater than 10 mg per dl, Total Leukocyte count greater than 4000 per mm3, platelet count greater than 100000 per mm3, adequate serum creatinine 0.6 to 1.5 mg per dl, ALT 0 to 45 U per L
6) Normal electrocardiogram
 
 
ExclusionCriteria 
Details  1) Those who are not willing to give consent
2) Carcinoma of nasopharynx, nasal cavity and paranasal sinuses
3) Patients with prior history of cancer, or synchronous malignancy
4) Prior history of lactose intolerance, enrolment in other trial or use of ayurvedic medicines
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
Mean change in total EORTC H&N35, EORTC H&N43, FACT-HN score in both treatment arms  From baseline to 6 months 
 
Secondary Outcome  
Outcome  TimePoints 
1. Mean change in expression of cytokines and epigenetic markers in both arms
2. Mean change in BDI scores
3. Frequency of adverse drug reactions reported with integrated Ayurveda care
4. Percentage compliance for add-on CAT therapies 
From baseline to 6 months  
 
Target Sample Size   Total Sample Size="100"
Sample Size from India="100" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2 
Date of First Enrollment (India)   16/08/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Rationale/Gaps in Existing Knowledge

Head and Neck Cancer (HNC) is a major public health concern in India, with late-stage presentation and poor survival rates. Conventional treatments (radiotherapy, surgery) are effective but cause debilitating side effects, negatively impacting patients’ Health-Related Quality of Life (HR-QoL). Patients seek complementary and alternative medicine (CAM) to manage these side effects, but its safety and efficacy with conventional treatment is unclear.

Novelty

The present study examines the integrative oncology approach by incorporating Comprehensive Ayurveda Treatment (CAT) as add-on with conventional HNC treatment in Central India. CAT, a holistic system, presents a novel and cost-effective array of therapies, including panchgavya, triphala, yoga etc. with potential applications in the management of HNCs.


Objectives

To compare the effectiveness of add-on CAT therapies with standard care versus only standard care in unresectable stage III – IVB head-neck squamous cell carcinoma (HNSCC) patients, w.r.t. health-related quality-of-life (HR-QoL) (primary), expression of biochemical and epigenetic markers, psychological distress, and its safety (secondary).

Methods

This study is an Assessor blind Open labelled Parallel group Randomized Controlled Trial, conducted at tertiary care centre. Total of 100 cases (50 in each arm) of unresectable histologically proven stage III - IVB HNCs will be recruited after a comprehensive screening process as per inclusion and exclusion criteria: involving haematological, radiographic etc. assessments for final inclusion and staging. They will be stratified: control arm receiving standard treatment with Concomitant Chemoradiotherapy (CRT) with modern volumetric arc modulated radiotherapy (VMAT) and trial arm receiving CAT therapies as add-on to standard treatment. Regular evaluations by clinicians and Ayurvedic experts will occur periodically, including physical examinations and relevant investigations (radiological, cytokines, epigenetic markers etc.) to monitor treatment progress and outcomes (QoL, Psychological distress, safety and efficacy).

Expected Outcomes

      1)  Improved patient QoL and symptom management in HNC

      2)  Evaluation of the feasibility, safety, and preliminary efficacy of this integrative paradigm in the clinical context.

             Develop evidence-based guidelines for integrating CAT therapies into HNC care, to empower these patients and improve HNC management in India.


 
Close